A recent study has shown that NPRA can enhance FAO in gastric cancer (GC) cells by protecting mitofusin 2 from protein degradation and promoting its mitochondrial localization, thereby leading to cisplatin resistance in GC cells [57]. Here, MFN2 is linked to gastric cancer.